

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
12 April 2007 (12.04.2007)

PCT

(10) International Publication Number
WO 2007/039175 A1

(51) International Patent Classification:

C07D 285/12 (2006.01) A61K 31/433 (2006.01)
C07D 417/12 (2006.01) A61P 3/10 (2006.01)
C07D 285/135 (2006.01) A61P 25/28 (2006.01)

(21) International Application Number:

PCT/EP2006/009301

(22) International Filing Date:

26 September 2006 (26.09.2006)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

05021785.0 6 October 2005 (06.10.2005) EP

(71) Applicant (for all designated States except US):
SANOFI-AVENTIS DEUTSCHLAND GMBH
[DE/DE]; Brüningstrasse 50, 95929 Frankfurt am Main
(DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **KEIL, Stefanie**
[DE/DE]; Sanofi-Aventis Deutschland GmbH, 65926
Frankfurt am Main (DE). **MATTER, Hans** [DE/DE];
Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt
am Main (DE). **SCHOENAFINGER, Karl** [DE/DE];
Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am
Main (DE). **URMANN, Matthias** [DE/DE]; Sanofi-Aven-
tis Deutschland GmbH, 65926 Frankfurt am Main (DE).
GLIEN, Maike [DE/DE]; Sanofi-Aventis Deutschland

GmbH, 65926 Frankfurt am Main (DE). **WENDLER,
Wolfgang** [DE/DE]; Sanofi-Aventis Deutschland GmbH,
65926 Frankfurt am Main (DE). **SCHAEFER, Hans-Lud-
wig** [DE/DE]; Sanofi-Aventis Deutschland GmbH, 65926
Frankfurt am Main (DE). **FALK, Eugen** [DE/DE];
Sanofi-Aventis Deutschland GmbH, 65926 Frankfurt am
Main (DE).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP,
KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT,
LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ,
NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU,
SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR,
TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT,
RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: N-[1 ,3,4]-THIADIAZOL-2-YL-BENZENE SULFONAMIDES, PROCESSES FOR THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS



(57) Abstract: The invention relates to N-[1 ,3,4]-thiadiazol-2-yl-benzene sulfonamides and to their physiologically acceptable salts and physiologically functional derivatives showing PPARdelta and PPARgamma agonist activity. What is described are compounds of the formula (I) in which the radicals are as defined, and their physiologically acceptable salts and processes for their preparations. The compounds are suitable for the treatment and/or prevention of disorders of fatty acid metabolism and glucose utilization disorders as well as of disorders in which insulin resistance is involved and demyelinating and other neurodegenerative disorders of the central and peripheral nervous system.